Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients.

Kidney Int

Division of Pulmonary Medicine, Rambam Health Care Campus and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology Haifa, Haifa, Israel.

Published: May 2009

Pulmonary hypertension in patients with end-stage renal disease on hemodialysis is a newly described entity. To determine its impact, we measured selected clinical variables in the survival of 127 hemodialysis patients. Overall, pulmonary hypertension was found in 37 of these patients; it was already prevalent in 17 of them before initiation of dialysis and was associated with severe cardiac dysfunction. In the other 20 it developed after dialysis began, without obvious cause. These two subgroups of patients had similar survival curves, which were significantly worse in comparison to those without pulmonary hypertension. Following the initiation of hemodialysis, 20 patients with otherwise matched clinical variables survived significantly longer than the 20 who developed pulmonary hypertension after dialysis began. With univariate analysis, significant hazard ratios were found for age at onset of hemodialysis therapy (1.7), valvular diseases (1.8), pulmonary hypertension prevalence before hemodialysis (3.6) and incident after hemodialysis (2.4) for predicting mortality. In a multivariable Cox proportional hazard model, the development of pulmonary hypertension both before and after initiation of hemodialysis had significantly increased odds ratios and remained an independent predictor of mortality. Our study shows the incidence of pulmonary hypertension, after initiation of hemodialysis therapy, is a strong independent predictor of mortality nearly equal to that associated with long-standing severe cardiac abnormalities.

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2009.10DOI Listing

Publication Analysis

Top Keywords

pulmonary hypertension
32
independent predictor
12
predictor mortality
12
hemodialysis patients
12
hypertension initiation
12
initiation hemodialysis
12
hemodialysis
9
pulmonary
8
patients pulmonary
8
hypertension patients
8

Similar Publications

Background: Penetrating cardiac trauma is an entity with high pre and intrahospital mortality due to complications such as cardiac tamponade and massive hemothorax. A ventricular septal defect (VSD) occurs in 1-5% of cases and can present early or late. The management strategy for VSD resulting from penetrating cardiac trauma is uncertain.

View Article and Find Full Text PDF

Catheter-based pulmonary artery denervation (PADN) has achieved promising outcomes to treat pulmonary hypertension (PH). We herein present stereotactic body radiotherapy (SBRT) as a novel noninvasive approach for PADN. A single fraction of 15 Gy, 20 Gy or 25 Gy was delivered for PADN in a thromboxane A2 (TxA2) - induced acute PH swine model.

View Article and Find Full Text PDF

Background: Heart failure (HF) is a high-burden clinical syndrome characterized by intravascular and extravascular congestion, impacting patients' outcomes. Current diagnostic methods for assessing intravascular congestion, including right heart catheterization (RHC), have some limitations. There is a need for accurate, stable, and widely applicable non-invasive measurement methods to improve HF diagnosis and treatment.

View Article and Find Full Text PDF

Sustained release of Ambrisentan Solid Lipid Nanoparticles for the treatment of Hypertension: Melt Emulsification Method.

Ann Pharm Fr

January 2025

SVKM's NMIMS School of Pharmacy and Technology Management Shirpur, Dhule, India-425405, India; SVKM Institute of Pharmacy, Dhule, Maharashtra-424001, India. Electronic address:

Objective: The beneficial usefulness is limited because of its deprived solubility and bioavailability. The recent work deals with the advancement of solid lipid nanoparticles of Ambrisentan for the effective therapy of pulmonary hypertension intended for oral delivery.

Material And Methods: The solid lipid nanoparticles of Ambrisentan were developed using the melt-emulsification method.

View Article and Find Full Text PDF

Background: A significant proportion of patients with isolated atrial flutter (AFL) will develop atrial fibrillation (AF) following cavotricuspid isthmus (CTI) ablation.

Objective: To determine whether concomitant pulmonary vein isolation (PVI) could reduce the incidence of new-onset atrial fibrillation (NOAF) in the setting of inducible AF following CTI ablation.

Methods: A total of 275 consecutive patients with isolated AFL who successfully underwent CTI ablation were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!